Cybin (HELP) Income from Non-Controlling Interests (2020 - 2025)

Cybin's (HELP) quarterly Income from Non-Controlling Interests came in at $715.85 in Q4 2024, down 67.45% on a QoQ basis from $2199.2 in Q3 2024.

Cybin (HELP) Income from Non-Controlling Interests (2020 - 2025) Analysis & Trends

Cybin (HELP) has 4 years of Income from Non-Controlling Interests data on file, last reported at $715.85 in Q4 2024.

  • Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $715.85 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$1.7 million (changed N/A YoY) and the FY2021 annual result came in at $53757.5, changed N/A from the prior year.
  • Income from Non-Controlling Interests slipped to $715.85 in Q4 2024, from $2199.2 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $25219.3 in Q2 2021 to a low of -$1.7 million in Q3 2022.
  • A 4-year average of -$254386.7 and a median of $1442.4 in 2020 frame the typical range for Income from Non-Controlling Interests.
  • Annual changes were most pronounced in 2021 — Income from Non-Controlling Interests soared 1648.42% — and 2022, when it plunged 1000.81%.
  • Tracing HELP's Income from Non-Controlling Interests over 4 years: stood at $1442.4 in 2020, then tumbled by 10564.29% to -$150937.8 in 2021, then sank by 1000.81% to -$1.7 million in 2022, then surged by 100.04% to $715.85 in 2024.
  • The last three Income from Non-Controlling Interests figures came in at $715.85 (Q4 2024), $2199.2 (Q3 2024), and $2193.4 (Q2 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 63.60 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Cybin 417.29 Mn 417.29 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2025 -2.92 Mn
Dec 31, 2024 715.85
Sep 30, 2024 2,199.16
Jun 30, 2024 2,193.42
Sep 30, 2022 -1.66 Mn
Sep 30, 2021 -150,937.77
Jun 30, 2021 25,219.34
Jun 30, 2020 1,442.41